Epocrates and M3 Create Global Physician Research Panel

It is recognized industry-wide for its honesty and sample representation, providing clients the ability to recruit respondents based on specialty, years in practice, geography, and other demographic variables.

M3 operates globally with physician communities across the world via various professional web portals, including m3 dot com, MDLinx dot com, Doctors dot net dot uk, Medquarter dot de, and Medigate dot net, which has enabled the development of a proprietary healthcare professional panel with international diversity and extensive reach. The new unified panel covers more than 70 countries with more than 1.7 million physicians globally, providing more accurate targeting and sample specificity, and will offer investors, research firms, and pharmaceutical marketers greater access to qualified physicians and other healthcare professionals in the top medical specialties, including oncology, cardiology, and family practice.

“An audit within the industry revealed that M3 has the same quality assurance and values that we uphold for our research business,” said Peter Brandt, interim president and CEO of Epocrates. “Together, we are elevating the integrity and delivery standards across the research industry.”

“Both companies have established deep relationships with panel members, providing faster turnaround and more quality responders all over the world,” said Aki Tomaru, CEO of M3. “The goal of this partnership is to create some of the best healthcare market research coverage globally, featuring more consistent and comprehensive solutions for the industry.”

Epocrates offers various mobile health software applications, mostly for health care providers, providing them reference information about drugs, diseases, and diagnostic tools. Among the software functions is checking for drug interactions, news feeds for product announcements and medical news, journal article lookup, and a mobile guide to ICD-9 and Current Procedural Terminology ("CPT") diagnosis codes. The company markets both free and multiple paid versions, and receives additional revenue from pharmaceutical companies.

Related Links:
Epocrates
M3